Independent 5-year pharmaceutical and healthcare industry forecasts for Oman.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Omani pharmaceutical and healthcare industry.
Competitive intelligence, Omani pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Omani market.
The Oman Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’
Key Benefits of Report
Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Oman to test other views – a key input for successful budgeting and strategic business planning in the Omani pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Omani Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Oman.
Exploit The Latest Competitive Omani Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Oman.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Oman
Oman has one of the most efficient healthcare systems in the Middle East & North Africa (MENA) region. This rapid growth (of around 10% per annum) of its pharmaceutical market is being driven predominately by a rapid increase in population and the growing contribution of the private sector, stimulated by the exclusion of expatriate workers from public healthcare schemes and the increased demand for medical tourism. Prescription and branded drugs continue to dominate the market, standing at more than 90% and 95% of the total value, respectively.
The recent Oman-US Free Trade Agreement (FTA) has also resulted in a marked improvement in Oman’s intellectual property (IP) rights legislation, including the implementation of a data exclusivity regime and tougher penalties for counterfeiters. This will serve to further boost import opportunities, especially for treatments of chronic diseases. However, the drug regulatory system in Oman is still considered to be below international standards, with multinational drugmakers claiming that it is opaque and somewhat arbitrary and that it unfairly provides high levels of protection to local manufacturers. Plans to harmonise the drug regulation process in the GCC could help standardise procedures in the country.
BMI’s adjusted Business Environment Rankings for the MENA region reveal that the Oman is in joint fourth place behind Saudi Arabia, Kuwait and South Africa. This is primarily due to forecasts of high market growth (of around 10% per annum), coupled with the country’s new intellectual property regime. Oman’s limited domestic manufacturing industry and lack of technological capabilities have also made the country an excellent investment opportunity for foreign drugmakers, although the outlook is tempered somewhat by the small overall market size.
Development in the country’s healthcare sector could increasingly focus on the provision of outsourced pharmaceutical production as the GCC begins to challenge markets such as India and China in this field. Gulf drugmakers have the advantage of being able to offer low-cost drugs, which have been manufactured to a high standard. Local player Oman Pharmaceutical Products Company (OPPC) is attempting to exploit this avenue through offering contract manufacturing to multinationals.
For more information, Please visit :
http://www.bharatbook.com/
